Overview: MERRF Mutation TestIntroduction: The MERRF Mutation Test detects MERRF mutations to diagnose mitochondrial disorders, causing seizures or muscle weakness. Aligned with 2023 United Mitochondrial Disease Foundation guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected MERRF syndrome.
Other Names: MERRF Assay, Mitochondrial Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MERRF mutation testing began in the 1990s with mitochondrial research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects MERRF mutations to diagnose mitochondrial disorders, guides treatment, and evaluates patients with seizures or muscle weakness.
Test Parameters: 1. MERRF Mutations
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of seizures, muscle weakness, or mitochondrial symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document seizures, muscle weakness, ataxia, or family history of mitochondrial disorders. Include current medications, especially antiepileptics.
Consent: Written consent required, detailing the tests purpose, mitochondrial disorder implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect MERRF mutations (e.g., MT-TK gene) in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for mitochondrial disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive MERRF mutations confirm mitochondrial disorder, guiding supportive care or genetic counseling. Negative results may require further genetic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, mitochondrial DNA sequencing, or EEG to confirm MERRF diagnosis.
Test Limitations: Not all mitochondrial mutations are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: UMDF Mitochondrial Guidelines, 2023; Neurology, DiMauro S, 2022.
